Z944 | T-type calcium channel blocker

CAS:
 1199236-64-0
Catalog Number:
 10-3994

Available Options

Size:PriceQuantity 
5 mg$90.00
25 mg$300.00
Request Quote / Bulk / Custom Size
Product Inquiry

Z944 (1199236-64-0) is a highly selective (70 fold over N-type) T-type calcium channel blocker (IC50 hCav3.2 = 50 nM).1 It was 2.5 to 4-fold more potent for the inactivated T-type channel than for the closed channel.  It was also selective against the Cav1.2, hERG, and Nav1.5 channels. Z944 potently suppressed seizures in absence epilepsy1 and temporal lobe epilepsy2 models. It reversed thermal hyperalgesia and conditioned place preference in a neuropathic pain model.3 Z944 reversed mechanical allodynia in a model of persistent inflammatory pain4 and displayed an antihyperalgesic effect in a model of trigeminal neuralgia5. Z944 significantly improved autism spectrum disorder-related behaviors via suppression of reticular thalamic hyperexcitability.6

References/CItations:

  1. Tringham et al. (2012), T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures; Sci. Transl. Med., 4 121ra19
  2. Casillas-Espinosa et al. (2015), Z944, a Novel Selective T-Type Calcium Channel Antagonist Delays the Progression of Seizures in the Amygdala Kindling Model; PLoS One, 10 e0130012
  3. LeBlanc et al. (2016), T-type calcium channel blocker Z944 restores cortical synchrony and thalamocortical connectivity in a rat model of neuropathic pain; Pain, 157 255
  4. Harding et al. (2021), T-type calcium channel antagonist, Z944, reduces spinal excitability and pain hypersensitivity; Br. J. Pharmacol., 178 3517
  5. Gambeta et al. (2022), Ca V 3.2 calcium channels contribute to trigeminal neuralgia; Pain, 163 2315
  6. Jang et al. (2025), Reticular thalamic hyperexcitability drives autism spectrum disorder behaviors in the Cntnap2 model of autism; Sci. Adv., 11 eadw4682
1199236-64-0, Cav3.2 blocker, PRAX-944, T-type calcium channel blocker, Ulixacaltamide, Z-944, Z944, Z944 supplier
CAS:
1199236-64-0
Catalog Number:
10-3994
Activity:
T-type Calcium Channel Blocker
Chemical Names:
N-[[1-[2-(tert-Butylamino)-2-oxoethyl]piperidin-4-yl]methyl]-3-chloro-5-fluorobenzamide
Alternate Name:
Ulixacaltamide; PRAX-944
Molecular Weight:
383.89
Molecular Formula:

C19H27ClFN3O2

Solubility:
Soluble in DMSO (>25 mg/ml)
Physical Properties:
White solid
Purity:

>98% HPLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for up to 2 years when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Z944 (1199236-64-0) is a highly selective (70 fold over N-type) T-type calcium channel blocker (IC50 hCav3.2 = 50 nM).1 It was 2.5 to 4-fold more potent for the inactivated T-type channel than for the closed channel.  It was also selective against the Cav1.2, hERG, and Nav1.5 channels. Z944 potently suppressed seizures in absence epilepsy1 and temporal lobe epilepsy2 models. It reversed thermal hyperalgesia and conditioned place preference in a neuropathic pain model.3 Z944 reversed mechanical allodynia in a model of persistent inflammatory pain4 and displayed an antihyperalgesic effect in a model of trigeminal neuralgia5. Z944 significantly improved autism spectrum disorder-related behaviors via suppression of reticular thalamic hyperexcitability.6

References/CItations:

  1. Tringham et al. (2012), T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures; Sci. Transl. Med., 4 121ra19
  2. Casillas-Espinosa et al. (2015), Z944, a Novel Selective T-Type Calcium Channel Antagonist Delays the Progression of Seizures in the Amygdala Kindling Model; PLoS One, 10 e0130012
  3. LeBlanc et al. (2016), T-type calcium channel blocker Z944 restores cortical synchrony and thalamocortical connectivity in a rat model of neuropathic pain; Pain, 157 255
  4. Harding et al. (2021), T-type calcium channel antagonist, Z944, reduces spinal excitability and pain hypersensitivity; Br. J. Pharmacol., 178 3517
  5. Gambeta et al. (2022), Ca V 3.2 calcium channels contribute to trigeminal neuralgia; Pain, 163 2315
  6. Jang et al. (2025), Reticular thalamic hyperexcitability drives autism spectrum disorder behaviors in the Cntnap2 model of autism; Sci. Adv., 11 eadw4682

STEM CELL

BOGO